Esomeprazoleï¼›A19447ï¼›119141-88-7ï¼›

5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2- pyridinyl) methyl) sulfinyl) -1H-benzimidazole;

6-Methoxy-2-[(R)-(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]-1H-benzoimidazoleï¼›

C₁₇H₁₉N₃O₃S

Esomeprazole is a proton pump inhibitor (brand name Nexium) developed and marketed in Sweden by AstraZeneca which is used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome. Esomeprazole is the S-enantiomer of omeprazole (brand name Prilosec/Losec) also developed and marketed by AstraZeneca, and AstraZeneca claims improved efficacy of this single enantiomer product over the racemic mixture of omeprazole. Generic version of Esomeprazole is available in many countries made by Ranbaxy Laboratories of India. Ranbaxy's generic version of Esomeprazole is sold in several countries of Europe and in emerging markets like India, Peru,Ecuador, Caribbean Islands, Nigeria, Africa, Srilanka, Cambodia and Myanmar under the brand name Raciper.
Esomeprazole is a proton pump inhibitor which reduces acid secretion through inhibition of ATPase in gastric parietal cells. By inhibiting the functioning of this enzyme, the drug prevents formation of gastric acid.
Medical use: The primary uses of esomeprazole are gastroesophageal reflux disease, treatment of duodenal ulcers caused by H. pylori, preventing of gastric ulcers in those on chronic NSAID therapy, and treatment of gastrointestinal ulcers associated with Crohn's disease.
Gastroesophageal reflux disease: Gastroesophageal Reflux Disease (GERD) is a condition in which the digestive acid in the stomach comes in contact with the esophagus (food pipe). The irritation caused by this disorder is known as heartburn. Long term contact between the acid and esophagus can cause permanent damage to the esophagus. Esomeprazole reduces the production of digestives acids, thus minimizing their effect on the esophagus.
Duodenal ulcers: Esomeprazole is combined with the antibiotics clarithromycin and amoxicillin (or metronidazole in penicillin-hypersensitive patients) in the 7-14 day eradication triple therapy for Helicobacter pylori. Infection by H. pylori is the causative factor in the majority of peptic and duodenal ulcers.